Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Sigma Healthcare (ASX:SIG) share price sinks 6% after profit guidance reversal

The Sigma Healthcare Ltd (ASX: SIG) share price has sunk into the red today after the business downgraded profit expectations.

The Sigma Healthcare Ltd (ASX: SIG) share price has sunk into the red today after the business downgraded profit expectations.

Subsequently, the Sigma share price is down 6.67% to $0.49.

SIG share price

Source: Rask Media SIG 1-year share price
Source: Rask Media SIG 1-year share price

Forget about growth

With ten months of FY22 complete, Sigma anticipates its underlying EBITDA result will be down 10% compared to FY21.

In FY21, Sigma achieved an underlying EBITDA of $81.1 million. Therefore today’s guidance implies an earnings result of around $72 million.

The updated profit guidance is a reversal from the 5% underlying EBITDA growth provided in September.

New software is no good

The business noted operational issues relating to a new Enterprise Resource Planning (ERP) system.

ERP’s assist businesses like Sigma manage operations including finance, human resources, supply chain and procurement across one system.

In theory, ERP’s should reduce administration and simplify business activities – not add to them.

However, the new system has only complicated operations.

“Unfortunately, this has had some significant impacts on our customers, and we are rectifying these issues as quickly as possible” – Interim CFO Jeff Sells

Sigma’s primary job is distributing prescription, over-the-counter and generic medications to hospitals, pharmacies and healthcare providers.

With the ERP not running properly, this has led to delays and subsequent one-off operating costs of $25-$30 million.

As a result of the cost increases, net debt for the year will be also be impacted.

Management noted that ERP issues have only been exacerbated by the impacts of the pandemic.

Potential sales boost in FY23

Sigma noted that the impacts will be largely confined to FY22, which ends on January 31.

However, delayed sales from FY22 will flow into FY23, which should abate as the year progresses.

“Notwithstanding this set-back, we remain confident in the future growth profile for Sigma” – Chairman Ray Gunston

My take

Two issues arise when implementing new software.

The first is transitioning existing records and data across. The second is training all of your employees on how to use a new system.

Imagine using Windows for 10 years. And then overnight your work changes its systems to Apple.

Sigma has obviously had some teething issues, and $25 million in extra costs is nothing to be sneezed at.

With the uncertainty of the ERP roll-out still over the business, I’ll be watching Sigma from the sidelines for now.

If you enjoyed this update, consider signing up for a free Rask account and accessing our full stock reports.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Lachlan does not have a financial or commercial interest in any of the companies or funds mentioned.
Skip to content